<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101787</url>
  </required_header>
  <id_info>
    <org_study_id>NL58067.068.16</org_study_id>
    <nct_id>NCT03101787</nct_id>
  </id_info>
  <brief_title>Early Initiation of Extracorporeal Life Support in Refractory OHCA</brief_title>
  <acronym>INCEPTION</acronym>
  <official_title>Early Initiation of Extracorporeal Life Support in Refractory OHCA (INCEPTION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Getinge Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite adequate conventional cardiopulmonary resuscitation (CCPR) and attempted&#xD;
      defibrillation, a considerable number of patients in cardiac arrest fail to achieve sustained&#xD;
      return of spontaneous circulation. The INCEPTION trial is a multicenter, randomized&#xD;
      controlled trial that will explore extracorporeal cardiopulmonary resuscitation (ECPR) in&#xD;
      patients in refractory out-of-hospital cardiac arrest (OHCA) presenting with ventricular&#xD;
      fibrillation or tachycardia. It aims to determine the effect on survival and neurological&#xD;
      outcome. Additionally, it will evaluate the feasibility and cost-effectiveness of ECPR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are approximately 275,000 cases of out-of-hospital cardiac arrest (OHCA) per year in&#xD;
      Europe, of which two-thirds have a primary cardiac origin. However, despite adequate&#xD;
      conventional cardiopulmonary resuscitation (CCPR) and attempted defibrillation, a&#xD;
      considerable number of these patients fail to achieve sustained return of spontaneous&#xD;
      circulation (ROSC).&#xD;
&#xD;
      Treatment of the underlying cause of the arrest, in most cases coronary artery occlusion, is&#xD;
      paramount. But in the absence of ROSC, the possibilities to perform these life-saving&#xD;
      interventions are limited. Continued CCPR is currently the standard of care for these&#xD;
      patients. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR) restores&#xD;
      circulation, with the potential to minimize (or even reversing) organ damage, prevent&#xD;
      re-arrest due to ischemia-triggered myocardial dysfunction and providing a bridge to possible&#xD;
      diagnosis and treatment. Several studies have demonstrated that ECPR is feasible and may be&#xD;
      advantageous with respect to survival and neurological outcome.&#xD;
&#xD;
      The INCEPTION trial aims to compare ECPR to CCPR in the population that is expected to&#xD;
      benefit the most from this intervention: young patients presenting with ventricular&#xD;
      fibrillation or tachycardia (VF/VT) and a refractory cardiac arrest. Furthermore, it will&#xD;
      provide data on the cost-effectiveness of this intervention, which to date has been&#xD;
      unavailable. Although the costs may prove to be high, the gain in quality-adjusted life years&#xD;
      (QALY's) may be substantial given the fact that most patients are relatively young and the&#xD;
      current alternative carries a poor prognosis. This can determine whether ECPR should be&#xD;
      pursued as a standard of care in patients with refractory arrest.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day survival rate with favorable neurological status</measure>
    <time_frame>30 days</time_frame>
    <description>Favorable neurological status is defined as 1 or 3 on the using Cerebral Performance Category scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QALY's</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Quality-adjusted-life-years using EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of ECPR and CCPR</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Using the Case Report Form, Productivity Cost Questionnaire (iPCQ) and Medical Consumption Questionnaire (iMCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival status at 3 months, 6 months and 1 year</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic status at 3 months, 6 months and 1 year</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Favorable neurological status is defined as 1 or 3 on the using Cerebral Performance Category scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Out-Of-Hospital Cardiac Arrest</condition>
  <condition>Sudden Cardiac Death</condition>
  <arm_group>
    <arm_group_label>CCPR protocol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).&#xD;
Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.&#xD;
No special preparations for the trial are needed before the patient's arrival.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECPR protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).&#xD;
Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).&#xD;
Time from arrest to start of cannulation is &lt; 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal cardiopulmonary resuscitation (ECPR)</intervention_name>
    <description>In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.&#xD;
The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.&#xD;
Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.&#xD;
Time from arrest to start of cannulation is &lt; 60 minutes.</description>
    <arm_group_label>ECPR protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 - ≤70 years&#xD;
&#xD;
          2. Witnessed OHCA&#xD;
&#xD;
          3. Initial rhythm of VF/VT or AED administered&#xD;
&#xD;
          4. Bystander BLS&#xD;
&#xD;
          5. No ROSC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ROSC&#xD;
&#xD;
          2. Terminal heart failure (NYHA III or IV)&#xD;
&#xD;
          3. Severe pulmonary disease (COPD GIII of GIV)&#xD;
&#xD;
          4. Oncological disease&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Bilateral femoral bypass surgery&#xD;
&#xD;
          7. Pre-arrest CPC-score of 3 or 4&#xD;
&#xD;
          8. Advanced directive&#xD;
&#xD;
          9. Multitrauma (ISS &gt;15)&#xD;
&#xD;
         10. Start cannulation &gt; 60 min after arrest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel van de Poll, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martje Suverein, MD</last_name>
    <phone>(+31)43 387 6385</phone>
    <email>martje.suverein@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martje Suverein, MD</last_name>
      <phone>+3143 387 6385</phone>
      <email>martje.suverein@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marcel van de Poll, MD, PhD</last_name>
      <email>marcel.vande.poll@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Martine Bol, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thijs Delnoij, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Lorusso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jos Maessen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel van de Poll, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Roekaerts, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Weerwind, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ka Yan Lam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Vlaar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Brandon Bravo Bruinsma, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Scholten, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Elzo Kraemer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bas van den Bogaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sakir Akin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corstiaan Den Uil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joris van der Heijden, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECPR</keyword>
  <keyword>Extracorporeal CardioPulmonary Resuscitation</keyword>
  <keyword>OHCA</keyword>
  <keyword>Out-of-Hospital Cardiac Arrest</keyword>
  <keyword>CPR</keyword>
  <keyword>CardioPulmonary Resuscitation</keyword>
  <keyword>ECMO</keyword>
  <keyword>ExtraCorporeal Membrane Oxygenation</keyword>
  <keyword>Refractory Cardiac Arrest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

